VBIV - VBI Vaccines Inc.
3.28 0.00 (0.00%)
After hours: 4:59PM EDT
| Previous Close | 3.22 |
| Open | 3.20 |
| Bid | 3.07 x 300 |
| Ask | 4.00 x 1000 |
| Day's Range | 3.17 - 3.32 |
| 52 Week Range | 3.04 - 5.10 |
| Volume | 81,706 |
| Avg. Volume | 118,732 |
| Market Cap | 210.627M |
| Beta | 1.31 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Benzinga•last month
ICYMI: Penny Stocks, Energy ETF, AR And VR Devices
In case you missed it, here are some of Benzinga's top stories from Thursday, March 15th, 2018. Energy Stocks And ETFs Struggle For energy investors, the weakness in energy stocks and ETFs that characterized ...
- Capital Cube•4 months ago
ETFs with exposure to VBI Vaccines, Inc. : December 26, 2017
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to VBI Vaccines, Inc. Here are 5 ETFs with the largest exposure to VBIV-US. Comparing the performance and risk of VBI Vaccines, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)
Capital Cube•4 months agoVBI Vaccines, Inc. :VBIV-US: Earnings Analysis: Q3, 2017 By the Numbers : December 25, 2017
Categories: Yahoo FinanceGet free summary analysis VBI Vaccines, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of VBI Vaccines, Inc. – Pieris Pharmaceuticals, Inc. and PDL BioPharma, Inc. (PIRS-US and PDLI-US) that have also reported for this period. Highlights Summary numbers: Revenues of USD 0.19 ... Read more (Read more...)
- Benzinga•5 months ago
VBI Vaccines Could Nearly Triple In Value On New Drug Launches, According To BMO
VBI Vaccines, Inc. - Ordinary Shares (NASDAQ: VBIV ) will release results on three clinical trials in the first half of 2018, presenting certain investment opportunities of an uncertain nature. Some on ...
- Zacks Small Cap Research•5 months ago
VBI: Multiple Platforms Yield a Portfolio of Vaccines
NASDAQ:VBIV VBI Vaccines, Inc. (NASDAQ:VBIV) is a Cambridge, Massachusetts-based biopharmaceutical company developing a portfolio of vaccines including solutions for hepatitis B, cytomegalovirus (CMV) ...
- Capital Cube•8 months ago
ETFs with exposure to VBI Vaccines, Inc. : August 28, 2017
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to VBI Vaccines, Inc. Here are 5 ETFs with the largest exposure to VBIV-US. Comparing the performance and risk of VBI Vaccines, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)
Capital Cube•8 months agoVBI Vaccines, Inc. :VBIV-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017
Categories: Yahoo FinanceGet free summary analysis VBI Vaccines, Inc. reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of VBI Vaccines, Inc. – Pieris Pharmaceuticals, Inc., PDL BioPharma, Inc. and Bioblast Pharma Ltd. (PIRS-US, PDLI-US and ORPN-US) that have also reported for this period. Highlights Summary numbers: ... Read more (Read more...)
- Capital Cube•8 months ago
ETFs with exposure to VBI Vaccines, Inc. : August 18, 2017
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to VBI Vaccines, Inc. Here are 5 ETFs with the largest exposure to VBIV-US. Comparing the performance and risk of VBI Vaccines, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)
Capital Cube•9 months agoVBI Vaccines, Inc. :VBIV-US: Earnings Analysis: Q1, 2017 By the Numbers : August 7, 2017
Categories: Yahoo FinanceGet free summary analysis VBI Vaccines, Inc. reports financial results for the quarter ended March 31, 2017. Highlights Summary numbers: Revenues of USD 0.13 million, Net Earnings of USD -8.64 million. Gross margins narrowed from -781.25% to -903.94% compared to the same period last year, operating (EBITDA) margins now -6,831.50% from -5,064.58%. Change in operating ... Read more (Read more...)